Please assess the completion status of the following clinical trial:

Trial Title: Safety, Tolerability, and Efficacy of Anti-Spike (S) SARS-CoV-2 Monoclonal Antibodies for Hospitalized Adult Patients With COVID-19

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE1/PHASE2
- Number of Arms: 4.0

Eligibility Criteria:
Key Inclusion Criteria:~* Has SARS-CoV-2-positive antigen or molecular diagnostic test (by validated SARS-CoV-2 antigen, RT-PCR, or other molecular diagnostic assay, using an appropriate sample such as NP, nasal, oropharyngeal \[OP\], or saliva) ≤72 hours prior to randomization and no alternative explanation for current clinical condition. A historical record of positive result from test conducted ≤72 hours prior to randomization is acceptable.~* Has symptoms consistent with COVID-19, as determined by investigator, with onset ≤10 days before randomization~* Hospitalized for ≤72 hours with at least 1 of the following at randomization; patients meeting more than one criterion will be categorized in the most severely affected category:~  1. Cohort 1A: With COVID-19 symptoms but not requiring supplemental oxygen~ 2. Cohort 1: Maintains O2 saturation \>93% on low-flow oxygen as defined in the protocol~ 3. Cohort 2: High-intensity oxygen therapy without mechanical ventilation as defined in the protocol~ 4. Cohort 3: On mechanical ventilation~Key Exclusion Criteria:~* Phase 1 Only: Patients maintaining O2 saturation \>94% on room air~* In the opinion of the investigator, unlikely to survive for \>48 hours from screening~* Receiving extracorporeal membrane oxygenation (ECMO)~* Has new-onset stroke or seizure disorder during hospitalization~* Initiated on renal replacement therapy due to COVID-19~NOTE: Other protocol defined inclusion / exclusion criteria apply

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- On Low-Flow Oxygen (Type: EXPERIMENTAL): Cohort 1 (C1): O2 saturation \>93% on low-flow oxygen via nasal cannula, simple face mask, or other similar device
- With COVID-19 symptoms but not requiring supplemental O2 (Type: EXPERIMENTAL): Cohort 1A (C1A): With COVID-19 symptoms but not requiring supplemental oxygen
- High O2 No Mechanical Ventilation (Type: EXPERIMENTAL): Cohort 2 (C2): On high-intensity oxygen (O2) therapy but not on mechanical ventilation
- On Mechanical Ventilation (Type: EXPERIMENTAL): Cohort 3 (C3): On mechanical ventilation

Based on this trial design, predict the completion outcome and termination type (if applicable).